The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Antihemophilic Globulin Market Research Report 2024
Synopsis
The recombinant antihemophilic globulin is a drug synthesized by gene recombination technology, which is used to treat patients with hemophilia A. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of clotting factor VIII.
Global Recombinant Antihemophilic Globulin market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Antihemophilic Globulin market research.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following steps: gene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Antihemophilic Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Segment by Type
Baikoc
Afstyla
Altuviiio
Segment by Application
Clinical Treatment
Drug Research
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Antihemophilic Globulin report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
The recombinant antihemophilic globulin is a drug synthesized by gene recombination technology, which is used to treat patients with hemophilia A. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of clotting factor VIII.
Global Recombinant Antihemophilic Globulin market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Antihemophilic Globulin market research.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following steps: gene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant Antihemophilic Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Segment by Type
Baikoc
Afstyla
Altuviiio
Segment by Application
Clinical Treatment
Drug Research
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Antihemophilic Globulin report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Recombinant Antihemophilic Globulin Market Overview
1.1 Product Overview and Scope of Recombinant Antihemophilic Globulin
1.2 Recombinant Antihemophilic Globulin Segment by Type
1.2.1 Global Recombinant Antihemophilic Globulin Market Value Comparison by Type (2023-2029)
1.2.2 Baikoc
1.2.3 Afstyla
1.2.4 Altuviiio
1.3 Recombinant Antihemophilic Globulin Segment by Application
1.3.1 Global Recombinant Antihemophilic Globulin Market Value by Application: (2023-2029)
1.3.2 Clinical Treatment
1.3.3 Drug Research
1.3.4 Others
1.4 Global Recombinant Antihemophilic Globulin Market Size Estimates and Forecasts
1.4.1 Global Recombinant Antihemophilic Globulin Revenue 2018-2029
1.4.2 Global Recombinant Antihemophilic Globulin Sales 2018-2029
1.4.3 Global Recombinant Antihemophilic Globulin Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Antihemophilic Globulin Market Competition by Manufacturers
2.1 Global Recombinant Antihemophilic Globulin Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Antihemophilic Globulin Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Antihemophilic Globulin Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Antihemophilic Globulin Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Antihemophilic Globulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Antihemophilic Globulin, Product Type & Application
2.7 Recombinant Antihemophilic Globulin Market Competitive Situation and Trends
2.7.1 Recombinant Antihemophilic Globulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Antihemophilic Globulin Players Market Share by Revenue
2.7.3 Global Recombinant Antihemophilic Globulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Antihemophilic Globulin Retrospective Market Scenario by Region
3.1 Global Recombinant Antihemophilic Globulin Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Antihemophilic Globulin Global Recombinant Antihemophilic Globulin Sales by Region: 2018-2029
3.2.1 Global Recombinant Antihemophilic Globulin Sales by Region: 2018-2023
3.2.2 Global Recombinant Antihemophilic Globulin Sales by Region: 2024-2029
3.3 Global Recombinant Antihemophilic Globulin Global Recombinant Antihemophilic Globulin Revenue by Region: 2018-2029
3.3.1 Global Recombinant Antihemophilic Globulin Revenue by Region: 2018-2023
3.3.2 Global Recombinant Antihemophilic Globulin Revenue by Region: 2024-2029
3.4 North America Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.4.1 North America Recombinant Antihemophilic Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Antihemophilic Globulin Sales by Country (2018-2029)
3.4.3 North America Recombinant Antihemophilic Globulin Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.5.1 Europe Recombinant Antihemophilic Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Antihemophilic Globulin Sales by Country (2018-2029)
3.5.3 Europe Recombinant Antihemophilic Globulin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Antihemophilic Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Antihemophilic Globulin Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Antihemophilic Globulin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.7.1 Latin America Recombinant Antihemophilic Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Antihemophilic Globulin Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Antihemophilic Globulin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Antihemophilic Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Antihemophilic Globulin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Antihemophilic Globulin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Antihemophilic Globulin Sales by Type (2018-2029)
4.1.1 Global Recombinant Antihemophilic Globulin Sales by Type (2018-2023)
4.1.2 Global Recombinant Antihemophilic Globulin Sales by Type (2024-2029)
4.1.3 Global Recombinant Antihemophilic Globulin Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Antihemophilic Globulin Revenue by Type (2018-2029)
4.2.1 Global Recombinant Antihemophilic Globulin Revenue by Type (2018-2023)
4.2.2 Global Recombinant Antihemophilic Globulin Revenue by Type (2024-2029)
4.2.3 Global Recombinant Antihemophilic Globulin Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Antihemophilic Globulin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Antihemophilic Globulin Sales by Application (2018-2029)
5.1.1 Global Recombinant Antihemophilic Globulin Sales by Application (2018-2023)
5.1.2 Global Recombinant Antihemophilic Globulin Sales by Application (2024-2029)
5.1.3 Global Recombinant Antihemophilic Globulin Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Antihemophilic Globulin Revenue by Application (2018-2029)
5.2.1 Global Recombinant Antihemophilic Globulin Revenue by Application (2018-2023)
5.2.2 Global Recombinant Antihemophilic Globulin Revenue by Application (2024-2029)
5.2.3 Global Recombinant Antihemophilic Globulin Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Antihemophilic Globulin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Shire (Baxter)
6.1.1 Shire (Baxter) Corporation Information
6.1.2 Shire (Baxter) Description and Business Overview
6.1.3 Shire (Baxter) Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Shire (Baxter) Recombinant Antihemophilic Globulin Product Portfolio
6.1.5 Shire (Baxter) Recent Developments/Updates
6.2 Bayer Healthcare
6.2.1 Bayer Healthcare Corporation Information
6.2.2 Bayer Healthcare Description and Business Overview
6.2.3 Bayer Healthcare Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayer Healthcare Recombinant Antihemophilic Globulin Product Portfolio
6.2.5 Bayer Healthcare Recent Developments/Updates
6.3 CSL
6.3.1 CSL Corporation Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 CSL Recombinant Antihemophilic Globulin Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Recombinant Antihemophilic Globulin Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Corporation Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Grifols Recombinant Antihemophilic Globulin Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Corporation Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Biogen Recombinant Antihemophilic Globulin Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Octapharma
6.6.1 Octapharma Corporation Information
6.6.2 Octapharma Description and Business Overview
6.6.3 Octapharma Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Octapharma Recombinant Antihemophilic Globulin Product Portfolio
6.7.5 Octapharma Recent Developments/Updates
6.8 Novo Nordisk
6.8.1 Novo Nordisk Corporation Information
6.8.2 Novo Nordisk Description and Business Overview
6.8.3 Novo Nordisk Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novo Nordisk Recombinant Antihemophilic Globulin Product Portfolio
6.8.5 Novo Nordisk Recent Developments/Updates
6.9 Greencross
6.9.1 Greencross Corporation Information
6.9.2 Greencross Description and Business Overview
6.9.3 Greencross Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Greencross Recombinant Antihemophilic Globulin Product Portfolio
6.9.5 Greencross Recent Developments/Updates
6.10 Kedrion
6.10.1 Kedrion Corporation Information
6.10.2 Kedrion Description and Business Overview
6.10.3 Kedrion Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Kedrion Recombinant Antihemophilic Globulin Product Portfolio
6.10.5 Kedrion Recent Developments/Updates
6.11 BPL
6.11.1 BPL Corporation Information
6.11.2 BPL Recombinant Antihemophilic Globulin Description and Business Overview
6.11.3 BPL Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.11.4 BPL Recombinant Antihemophilic Globulin Product Portfolio
6.11.5 BPL Recent Developments/Updates
6.12 Hualan Bio
6.12.1 Hualan Bio Corporation Information
6.12.2 Hualan Bio Recombinant Antihemophilic Globulin Description and Business Overview
6.12.3 Hualan Bio Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Hualan Bio Recombinant Antihemophilic Globulin Product Portfolio
6.12.5 Hualan Bio Recent Developments/Updates
6.13 RAAS
6.13.1 RAAS Corporation Information
6.13.2 RAAS Recombinant Antihemophilic Globulin Description and Business Overview
6.13.3 RAAS Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.13.4 RAAS Recombinant Antihemophilic Globulin Product Portfolio
6.13.5 RAAS Recent Developments/Updates
6.14 Baxalta
6.14.1 Baxalta Corporation Information
6.14.2 Baxalta Recombinant Antihemophilic Globulin Description and Business Overview
6.14.3 Baxalta Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Baxalta Recombinant Antihemophilic Globulin Product Portfolio
6.14.5 Baxalta Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Antihemophilic Globulin Industry Chain Analysis
7.2 Recombinant Antihemophilic Globulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Antihemophilic Globulin Production Mode & Process
7.4 Recombinant Antihemophilic Globulin Sales and Marketing
7.4.1 Recombinant Antihemophilic Globulin Sales Channels
7.4.2 Recombinant Antihemophilic Globulin Distributors
7.5 Recombinant Antihemophilic Globulin Customers
8 Recombinant Antihemophilic Globulin Market Dynamics
8.1 Recombinant Antihemophilic Globulin Industry Trends
8.2 Recombinant Antihemophilic Globulin Market Drivers
8.3 Recombinant Antihemophilic Globulin Market Challenges
8.4 Recombinant Antihemophilic Globulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
